Assessing Two Coenzyme Q10 Products in Men and Women

NCT07530250 | Not Yet Recruiting

• 1 other identifier: MB-2580
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to compare the relative bioavailability of coenzyme Q10 (CoQ10) from acute administrations of a CoQ10 product designed for enhanced absorption versus a standard CoQ10 product in healthy men and women. Participants will be asked to come to the clinical on five different occasions, including a screening visit (visit 1, -7 days), two test 1 visits (visits 2 and 3, days 0 and 1), and two test 2 visits (visits 4 and 5, days 7 and 8). During the start of each test visit (visits 2 and 4), the participant will consume each study product with water and a standardized breakfast meal. Then, blood samples will be collected over a 10-hour period, and a standardized lunch, dinner, and snacks will be provided. The participant will return to the clinic the next morning for a blood draw 24 hours after the study product ingestion from the previous day. The same procedures will be repeated 7 to 14 days later with the other study product.

Conditions

CoQ10 Blood Levels

Outcome Measures

Primary Outcomes (1)

• Total area under the curve (AUC) for plasma CoQ10

  Difference between conditions in the total AUC for plasma CoQ10 from 0 to 24 h where t = 0 is the time of study product ingestion

  7 to 14 days between conditions

Secondary Outcomes (5)

• Incremental area under the curve (iAUC) for plasma CoQ10

  7 to 14 days between conditions

• Net incremental area under the curve (iAUC) for plasma CoQ10

  7 to 14 days between conditions

• Unadjusted maximum concentration (Cmax) for plasma CoQ10

  7 to 14 days between conditions

• Baseline-adjusted maximum concentration (Cmax) for plasma CoQ10

  7 to 14 days between conditions

• Time to maximum concentration (Tmax) for plasma CoQ10

  7 to 14 days between conditions

Study Arms (2)

Experimental - high absorption CoQ10 product

EXPERIMENTAL

100 mg CoQ10 product designed for high absorption (administered as two 50 mg capsules)

Dietary Supplement: high absorption CoQ10 product

Active Comparator - standard CoQ10 product

ACTIVE COMPARATOR

100 mg standard CoQ10 product (administered as two 50 mg capsules)

Dietary Supplement: standard CoQ10 product

Interventions

high absorption CoQ10 product DIETARY_SUPPLEMENT

100 mg CoQ10 product designed for high absorption (administered as two 50 mg capsules)

Experimental - high absorption CoQ10 product

standard CoQ10 product DIETARY_SUPPLEMENT

100 mg standard CoQ10 product (administered as two 50 mg capsules)

Active Comparator - standard CoQ10 product

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, between 21 and 65 y of age.
• Individual has a BMI of 18.5 to 34.9 kg/m2.
• Individual has a score ≥7 on the Vein Access Scale.
• Individual is willing to discontinue any dietary supplement use for two weeks prior to visit 2 and throughout the end of the testing period.
• Individual is judged by the Investigator to be in generally good health on the basis of medical history and screening/baseline measurements.
• Individual understands the study procedures, including maintaining usual physical activity pattern and refraining from vigorous physical activity for 24 h prior to each clinic visit requiring a blood draw. Signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

You may not qualify if:

• Individual has any gastrointestinal condition that could potentially interfere with absorption of the study product (e.g., inflammatory bowel syndrome, celiac disease, history of gastric bypass surgery).
• Individual has a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, or stroke), pulmonary, renal, hepatic, or biliary disorders.
• Individual has had any major trauma or surgical event within 12 weeks prior to screening/baseline (visit 1).
• Individual has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
• Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg) at screening/baseline (visit 1).
• Individual has a laboratory test result of clinical significance at screening/baseline (visit 1) based on the judgment of the Principal Investigator or qualified designee.
• Individual has signs or symptoms of an active infection of clinical significance (e.g., urinary tract or respiratory) within five days prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have been resolved for at least five days and, if antibiotics were prescribed, antibiotic therapy has been completed at least 7 days prior to the test visit.
• Individual has unstable use (defined as initiation or change in dose, agent, or regimen) of statin therapy within 3 months of visit 1.
• Individual uses medications or dietary supplements known to interfere with CoQ10 metabolism within 14 days prior to screening/baseline (visit 1) and throughout the study period, including, but not limited to, lipid-lowering (stable dose of statin therapy is allowed), anti-hypertensive, hypoglycemic, anti-coagulant, and psychotherapeutic therapies. For all other medications, individual must be on a stable dose for at least 3 months prior to visit 1.
• Use of any prescription medication with known effects on appetite or weight (e.g., oral steroids, weight loss medications, etc.) within 3 months of visit 1. A stable dose of selective serotonin reuptake inhibitors ≥3 months is allowed.
• Individual has lost ≥4.5 kg (10 lbs.) in the previous 3 months.
• Use of tobacco/nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 6 months of visit 1. Occasional use (defined as less than once per week) within 6 months of visit 1 is allowed but requires that the participant refrain for 24 hours prior to and during test visits.
• Individual follows a restricted diet (e.g., vegetarian, vegan, Atkins, etc.).
• Individual is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
• Individual has a known allergy or sensitivity to any ingredients in the study products or standardized meals/snacks.

Sponsors & Collaborators

• Midwest Center for Metabolic and Cardiovascular Research: lead
• Pharmavite LLC: collaborator

Study Sites (1)

Biofortis Clinical Research

Addison, Illinois, 60101, United States

Location

Central Study Contacts

Caryn Adams, MPH

CONTACT

6304696600; cwolfe@mbclinicalresearch.com

Sara Campbell, MPH

CONTACT

6304696600; scampbell@mbclinicalresearch.ocm

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2026
• First Posted: April 15, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: April 17, 2026

Record last verified: 2026-04

Locations

US (1)